Indy

Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest defenseworld.net · about 9 hours ago

NVIDIA Corporation $NVDA Stock Holdings Lessened by Bowen Hanes & Co. Inc.

Bowen Hanes and Co. Inc. reduced its holdings in NVIDIA Corporation (NASDAQ: NVDA) by 18.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 609,815 shares of the computer hardware maker's stock after selling 137,730 shares during the period. NVIDIA makes up

Read full story ↗ Research NVDA

Stocks

More recent coverage

Page 74
VNOM seekingalpha.com · about 9 hours ago

Viper Energy: More Acquisitions

Viper Energy, Inc. has completed several acquisitions. The latest was Riverbend. Recent deals, including the Riverbend acquisition, were likely negotiated before the sharp rise in commodity prices. VNOM's acquisition-driven growth is well-timed for a 'higher for longer' commodity price environment.

Read source ↗
NVDA 247wallst.com · about 9 hours ago

Analyst: If SpaceX Delivers Even a Quarter of Elon Musk's Promised Compute, Nvidia Could Hit $1 Trillion in Revenue

Elon Musk used SpaceX‘s (NASDAQ:SPCX | SPCX Price Prediction) first-ever public earnings call on August 4, 2026 to commit that the company will build its AI computing platform exclusively on NVIDIA‘s (NASDAQ:NVDA) Vera Rubin architecture, and floated a tentative target of 20 gigawatts of power and cooling capacity online by the end of 2027.

Read source ↗
PLX prnewswire.com · about 9 hours ago

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.

Read source ↗
FRG globenewswire.com · about 9 hours ago

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

DEER PARK, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has licensed U.S. rights to rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals (“Auson”). ASN-001 is under development for the treatment of proliferating superficial infantile hemangiomas.

Read source ↗
CMC prnewswire.com · about 9 hours ago

CMC Highlights Position as a Leading, Early-Stage Construction Solutions Provider and Unveils Long-Term Financial Targets at 2026 Investor Day

IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- CMC (NYSE: CMC) (the "Company") today will host its 2026 Investor Day in New York City, where members of the Company's leadership team will outline CMC's strategic vision, growth opportunities, capital allocation framework, and long-term financial targets. "Over the last several years, we have taken deliberate steps to transform CMC into an industry-leading provider of solutions across the early-stage construction ecosystem.

Read source ↗
GIL globenewswire.com · about 9 hours ago

GIL Legal News: Gildan Hit with Securities Fraud Investigation over Alleged Misrepresentations about its Revenue – Contact BFA Law

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into Gildan Activewear Inc. (NYSE:GIL) for potential securities fraud after its significant stock drop. If you invested in Gildan, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/gildan-class-action-lawsuit.

Read source ↗
HSBC proactiveinvestors.co.uk · about 9 hours ago

Citi downgrades HSBC to 'neutral' after 40% run

Citi has downgraded HSBC Holdings PLC (LSE:HSBA, NYSE:HSBC) to 'neutral' from 'buy', arguing that the shares need a breather after one of the strongest runs in the European banking sector this year. The stock is up 40% since January, and the bank now trades on roughly 11 times forward earnings and 2.2 times price to tangible book for a return on tangible equity of about 18% to 19%.

Read source ↗
EMBC globenewswire.com · about 9 hours ago

EMBC Legal News: Embecta Hit with Securities Fraud Class Action over Alleged Misrepresentations about its Insulin Pens – Contact BFA Law

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.

Read source ↗
MTRN businesswire.com · about 9 hours ago

Materion Corporation Reports Record Second-Quarter 2026 Financial Results and Raises Full-Year Outlook

MAYFIELD HEIGHTS, Ohio--(BUSINESS WIRE)--Materion Corporation (NYSE: MTRN) today reported strong second-quarter 2026 financial results and raised its full-year outlook. Financial Summary Net sales were $613.9 million versus $431.7 million in the prior year period; value-added sales1 were $308.2 million versus $269.0 million in the prior year period Net income of $38.8 million, or $1.84 per share, diluted, versus $25.1 million, or $1.21 per share, in the prior year period; adjusted earnings of $.

Read source ↗
← Newer
Older →